


**Financial Statements 2025-2026**  
**Second Quarter**  
**(Unaudited)**



**SQUARE PHARMACEUTICALS PLC.**  
**(Consolidated and Separate)**



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Financial Position

As at 31 December 2025

Particulars	Notes	31 Dec 2025 Taka	30 Jun 2025 Taka
<b>ASSETS</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	02	34,534,285,616	31,687,439,566
Investment in Associates	03	21,758,703,861	20,298,223,689
Investment in Marketable Securities	04	10,807,812,506	10,045,505,012
Long Term Investment - Others	05	15,151,733,677	10,222,623,532
		<b>82,252,535,660</b>	<b>72,253,791,799</b>
<b>Current Assets:</b>			
Inventories	06	12,912,545,701	13,059,201,630
Trade Receivables		2,281,428,801	2,236,196,774
Other Receivables	07	2,958,980,329	1,874,631,768
Advances, Deposits and Prepayments	08	1,734,407,173	1,995,278,987
Cash and Cash Equivalents	09	59,665,325,080	55,396,306,657
		<b>79,552,687,084</b>	<b>74,561,615,816</b>
<b>TOTAL ASSETS</b>		<b>161,805,222,744</b>	<b>146,815,407,615</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY:</b>			
Share Capital		8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
Reserves		2,988,926,579	2,156,958,554
Retained Earnings	10	130,070,818,605	126,893,437,592
<b>Attributable to Equity Holders</b>		<b>143,959,720,284</b>	<b>139,950,371,246</b>
Non-Controlling Interests	11	7,470,722	5,438,329
<b>TOTAL EQUITY</b>		<b>143,967,191,006</b>	<b>139,955,809,575</b>
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities</b>			
Long Term Loan	12.1	-	200,000,000
Deferred Tax Liabilities	13	1,033,761,451	836,115,073
		<b>1,033,761,451</b>	<b>1,036,115,073</b>
<b>Current Liabilities</b>			
Long Term Loan - Current Portion	12.2	512,486,309	625,501,239
Trade Payables		1,285,453,507	1,374,848,601
Other Payables	14	12,562,700,897	2,043,475,207
Current Tax Liabilities	15	1,934,782,269	1,306,637,831
Accrued Expenses	16	287,016,305	239,575,083
Unclaimed Dividend		221,831,000	233,445,006
		<b>16,804,270,287</b>	<b>5,823,482,967</b>
<b>TOTAL LIABILITIES</b>		<b>17,838,031,738</b>	<b>6,859,598,040</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>161,805,222,744</b>	<b>146,815,407,615</b>
<b>Net Assets Value (NAV) per Share</b>	28	<b>162.41</b>	<b>157.88</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Six-month Period Ended 31 December 2025

Particulars	Notes	Six-Month Result		2nd Quarter Result	
		July'25 - Dec'25	July'24 - Dec'24	Oct'25 - Dec'25	Oct'24 - Dec'24
		Taka	Taka	Taka	Taka
<b>Net Revenue</b>	17	<b>43,381,040,302</b>	<b>37,717,778,672</b>	<b>21,794,427,595</b>	<b>19,970,891,107</b>
Cost of Goods Sold	18	(21,837,452,898)	(19,893,431,304)	(11,494,370,564)	(11,066,042,141)
<b>Gross Profit</b>		<b>21,543,587,404</b>	<b>17,824,347,368</b>	<b>10,300,057,031</b>	<b>8,904,848,966</b>
Selling and Distribution Expenses	19	(7,167,993,428)	(6,052,370,907)	(3,495,557,493)	(2,994,473,111)
Administrative Expenses	20	(1,053,154,617)	(872,651,157)	(506,182,051)	(436,013,610)
Finance Cost	21	(58,071,279)	(127,200,832)	(26,542,650)	(58,405,306)
<b>Operating Expenses</b>		<b>(8,279,219,324)</b>	<b>(7,052,222,896)</b>	<b>(4,028,282,194)</b>	<b>(3,488,892,027)</b>
<b>Profit before Other Operating Income</b>		<b>13,264,368,080</b>	<b>10,772,124,472</b>	<b>6,271,774,837</b>	<b>5,415,956,939</b>
Other Operating Income	22	96,185,695	227,776,534	65,692,630	16,521,154
<b>Profit from Operations</b>		<b>13,360,553,775</b>	<b>10,999,901,006</b>	<b>6,337,467,467</b>	<b>5,432,478,093</b>
Income from Investments	23	3,620,298,765	3,051,387,881	1,882,769,888	1,590,587,236
<b>Profit before contribution to WPPF &amp; WWF</b>		<b>16,980,852,540</b>	<b>14,051,288,887</b>	<b>8,220,237,355</b>	<b>7,023,065,329</b>
Contribution to WPPF & WWF	24	(802,569,628)	(665,805,097)	(387,513,978)	(332,994,252)
<b>Profit before Tax</b>		<b>16,178,282,912</b>	<b>13,385,483,790</b>	<b>7,832,723,377</b>	<b>6,690,071,077</b>
Current Tax (Expense)		(2,759,822,794)	(2,424,802,712)	(1,363,932,531)	(1,213,618,964)
Deferred Tax (Expense) / Income		(202,129,196)	68,899,866	(60,294,676)	29,440,774
<b>Income Tax Expense</b>	25	<b>(2,961,951,990)</b>	<b>(2,355,902,846)</b>	<b>(1,424,227,207)</b>	<b>(1,184,178,190)</b>
<b>Profit after Tax</b>		<b>13,216,330,922</b>	<b>11,029,580,944</b>	<b>6,408,496,170</b>	<b>5,505,892,887</b>
Profit from Associate Undertakings	03	1,460,480,172	1,666,822,114	863,718,501	1,097,859,900
<b>Profit for the Period</b>		<b>14,676,811,094</b>	<b>12,696,403,058</b>	<b>7,272,214,671</b>	<b>6,603,752,787</b>
Net Unrealised Gain/(Loss) on Marketable Securities	26	(25,402,647)	107,125,409	(1,152,774,808)	(612,157,967)
Translation Adjustment for the Period	27	(5,616,435)	26,700,706	(2,494,899)	(115,257)
<b>Other Comprehensive Income</b>		<b>(31,019,082)</b>	<b>133,826,115</b>	<b>(1,155,269,707)</b>	<b>(612,273,224)</b>
<b>Total Comprehensive Income</b>		<b>14,645,792,012</b>	<b>12,830,229,173</b>	<b>6,116,944,964</b>	<b>5,991,479,563</b>
<b>Profit for the Period Attributable to:</b>					
Equity Holders of the Company		14,674,754,946	12,694,845,491	7,271,192,284	6,602,927,921
Non-Controlling Interest		2,056,148	1,557,567	1,022,387	824,866
		<b>14,676,811,094</b>	<b>12,696,403,058</b>	<b>7,272,214,671</b>	<b>6,603,752,787</b>
<b>Total Comprehensive Income Attributable to:</b>					
Equity Holders of the Company		14,643,759,619	12,828,677,248	6,115,971,418	5,990,666,397
Non-Controlling Interest		2,032,393	1,551,925	973,546	813,166
		<b>14,645,792,012</b>	<b>12,830,229,173</b>	<b>6,116,944,964</b>	<b>5,991,479,563</b>
<b>Earnings Per Share (EPS)</b>	29	<b>16.56</b>	<b>14.32</b>	<b>8.20</b>	<b>7.45</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Changes in Equity

For the Six-month Period Ended 31 December 2025

Amount in Taka

Particulars	Attributable to Equity Holders									Non-	Total Equity
	Share Capital	Share Premium	Reserves					Retained Earnings	Total	Controlling Interests	
			General	Fair Value	Tax Holiday	Translation	Sub-total				
As At 01 July 2024	8,864,510,100	2,035,465,000	105,878,200	(275,040,481)	951,511,612	97,906,017	880,255,348	114,139,071,906	125,919,302,354	2,318,478	125,921,620,832
Profit for the Period	-	-	-	-	-	-	-	12,694,845,491	12,694,845,491	1,557,567	12,696,403,058
Other Comprehensive Income	-	-	-	107,131,050	-	26,700,707	133,831,757	-	133,831,757	(5,641)	133,826,116
Cash Dividend (2023-24)	-	-	-	-	-	-	-	(9,750,961,110)	(9,750,961,110)	-	(9,750,961,110)
Transferred to Tax Holiday Reserve	-	-	-	-	723,081,191	-	723,081,191	(723,081,191)	-	-	-
As At 31 December 2024	8,864,510,100	2,035,465,000	105,878,200	(167,909,431)	1,674,592,803	124,606,724	1,737,168,296	116,359,875,096	128,997,018,492	3,870,404	129,000,888,896
As At 01 July 2025	8,864,510,100	2,035,465,000	105,878,200	(506,017,046)	2,414,156,028	142,941,372	2,156,958,554	126,893,437,592	139,950,371,246	5,438,329	139,955,809,575
Profit for the Period	-	-	-	-	-	-	-	14,674,754,946	14,674,754,946	2,056,148	14,676,811,094
Other Comprehensive Income	-	-	-	(25,378,892)	-	(5,616,435)	(30,995,327)	3,001,539	(27,993,788)	(23,755)	(28,017,543)
Cash Dividend (2024-25)	-	-	-	-	-	-	-	(10,637,412,120)	(10,637,412,120)	-	(10,637,412,120)
Transferred to Tax Holiday Reserve	-	-	-	-	862,963,352	-	862,963,352	(862,963,352)	-	-	-
As At 31 December 2025	8,864,510,100	2,035,465,000	105,878,200	(531,395,938)	3,277,119,380	137,324,937	2,988,926,579	130,070,818,605	143,959,720,284	7,470,722	143,967,191,006

The annexed notes form an integral part of these financial statements

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Cash Flows For the Six-month Period Ended 31 December 2025

Particulars	Notes	Amounts in Taka	
		July'25 - Dec'25	July'24 - Dec'24
<b>Cash Flows from Operating Activities:</b>			
Receipts from Customers		50,143,629,116	43,488,770,640
Receipts from Others		104,561,878	35,222,668
Payments to Suppliers		(15,758,382,073)	(16,232,342,292)
Payments for Manufacturing and Operating Expenses		(13,025,436,240)	(11,553,272,186)
Payment of Value Added Tax		(6,556,920,162)	(5,888,888,824)
<b>Cash Generated from Operations</b>		<b>14,907,452,519</b>	<b>9,849,490,006</b>
Interest Paid		(62,783,792)	(132,285,858)
Payment of Income Tax		(2,131,678,356)	(1,862,114,225)
Payment of WPPF & WF		(1,050,000,000)	(536,159,925)
Others		(229,111)	16,578,750
<b>Net Cash from Operating Activities</b>		<b>11,662,761,260</b>	<b>7,335,508,748</b>
<b>Cash Flows from Investing Activities:</b>			
Purchase of Property, Plant and Equipment		(3,887,944,651)	(3,467,778,772)
Proceeds from Sale of Property, Plant and Equipment		16,037,884	22,309,353
Long Term Investment - Others		(4,929,110,145)	(540,102,706)
Investment in Marketable Securities		(788,012,069)	(318,920,914)
Interest Received		2,425,735,244	2,708,416,424
Dividends Received		96,530,012	127,564,112
<b>Net Cash from/(Used in) Investing Activities</b>		<b>(7,066,763,725)</b>	<b>(1,468,512,503)</b>
<b>Cash Flows from Financing Activities:</b>			
Payment of Dividend for preceding years		(11,614,006)	(5,871,856)
Proceeds from/(Payment of) Term Loan		(313,014,930)	(298,420,282)
<b>Net Cash Used in Financing Activities</b>		<b>(324,628,936)</b>	<b>(304,292,138)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>		<b>4,271,368,599</b>	<b>5,562,704,107</b>
Cash and Cash Equivalents at 01 July	09	55,396,306,657	52,013,459,742
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents		(2,350,176)	176,672,654
<b>Cash and Cash Equivalents at 31 December</b>	09	<b>59,665,325,080</b>	<b>57,752,836,503</b>
<b>Net Operating Cash Flow (NOCF) per Share</b>	30	<b>13.16</b>	<b>8.28</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary

**SQUARE PHARMACEUTICALS PLC.**

AND ITS SUBSIDIARIES

**Notes to the Consolidated Financial Statements**  
**As at and For the Six-month Period Ended 31 December 2025****01. Basis of Preparation of the Interim Financial Statements:**

These Financial Statements are the unaudited consolidated interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913; Square Pharmaceuticals Kenya EPZ Ltd., incorporated in Kenya under Companies Act, 2015; Square Lifesciences Ltd., incorporated in Bangladesh under Companies Act, 1994, and Samson Pharma Inc., incorporated under Revised Corporation Code of the Philippines, 2019 for the 2nd Quarter Ended on December 31, 2025. These are prepared in accordance with IAS 34 - 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2025, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below. Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understand that the business is growing every year that means the assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if disposed at reporting date. At present, there is no intention to dispose these assets. Therefore, it is not required to record the impairment gain.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period. The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

**Foreign Currency Translation:**

Financials of foreign subsidiaries have been drawn in respective functional currencies. These Financials are converted in BDT to consolidate with the Financials of the parent company. 1 KES = BDT 0.947213 and 1 PHP = BDT 2.084909.

**02. Consolidated Property, Plant and Equipment: Tk. 34,534,285,616****Cost:**

Opening Balance

Translation Adjustments to opening balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**Accumulated Depreciation:**

Opening Balance

Translation Adjustments to opening balance

Charged for the Period/Year

Disposal/Transfer during the Period/Year

**Net Book Value**

Consolidated Property, Plant and Equipment in Transit (Note - 02.1)

Consolidated Capital Work-in-Progress (Note - 02.2)

**02.1 Consolidated Property, Plant and Equipment in Transit: Tk. 732,750,865**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**02.2 Consolidated Capital Work-in-Progress: Tk. 8,542,424,609****02.2.1 Consolidated Building and Other Constructions: Tk. 4,593,493,174**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**02.2.2 Consolidated Plant & Machinery: Tk. 3,948,931,435**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**03. Consolidated Investment in Associates: Tk. 21,758,703,861**

Opening Balance

Add: Profit/(Loss) during the Period/Year:

Square Textiles PLC.

Square Fashions Ltd.

Square Hospitals Ltd.

Less: Dividend received during the Period/Year

**Proportion of Ownership**

46.36%

48.63%

49.94%

**04. Consolidated Investment in Marketable Securities: Tk. 10,807,812,506****04.1 Cost: Tk. 11,433,014,991**

Opening Balance

Addition during the Period/Year

Sold during the Period/Year

	31 Dec 2025	30 Jun 2025
	52,656,099,111	50,654,228,044
	(3,836,241)	78,458,441
	1,585,744,495	2,093,961,327
	54,238,007,365	52,826,647,812
	(54,144,720)	(170,548,701)
<b>Tk.</b>	<b>54,183,862,645</b>	<b>52,656,099,111</b>
	27,898,058,892	25,796,547,715
	(1,056,409)	15,799,086
	1,069,499,843	2,200,720,986
	28,966,502,326	28,013,067,787
	(41,749,823)	(115,008,895)
<b>Tk.</b>	<b>28,924,752,503</b>	<b>27,898,058,892</b>
	25,259,110,142	24,758,040,219
	732,750,865	1,291,063,589
	8,542,424,609	5,638,335,758
<b>Tk.</b>	<b>34,534,285,616</b>	<b>31,687,439,566</b>
	1,291,063,589	1,118,740,924
	1,208,099,198	1,507,432,783
	2,499,162,787	2,626,173,707
	(1,766,411,922)	(1,335,110,118)
<b>Tk.</b>	<b>732,750,865</b>	<b>1,291,063,589</b>
	2,983,003,892	1,317,735,384
	1,611,042,534	1,833,001,113
	4,594,046,426	3,150,736,497
	(553,252)	(167,732,605)
<b>Tk.</b>	<b>4,593,493,174</b>	<b>2,983,003,892</b>
	2,655,331,866	455,849,227
	1,293,599,569	2,200,184,173
	3,948,931,435	2,656,033,400
	-	(701,534)
<b>Tk.</b>	<b>3,948,931,435</b>	<b>2,655,331,866</b>
<b>Tk.</b>	<b>8,542,424,609</b>	<b>5,638,335,758</b>
	20,298,223,689	17,397,060,559
	150,256,680	590,131,737
	1,116,414,636	2,290,756,140
	193,808,856	312,872,619
	1,460,480,172	3,193,760,496
	-	(292,597,366)
<b>Tk.</b>	<b>21,758,703,861</b>	<b>20,298,223,689</b>
	10,640,822,032	9,615,982,078
	903,663,562	1,174,740,948
	(111,470,603)	(149,900,993)
<b>Tk.</b>	<b>11,433,014,991</b>	<b>10,640,822,033</b>

	31 Dec 2025	30 Jun 2025
<b>04.2 Market Value: Tk. 10,807,812,506</b>		
Opening Balance	10,045,505,012	9,292,402,647
Addition during the Period/Year	877,958,987	1,034,509,173
Sold during the Period/Year	(115,651,493)	(281,406,808)
<b>Tk.</b>	<b>10,807,812,506</b>	<b>10,045,505,012</b>
<b>05. Consolidated Long Term Investment - Others: Tk. 15,151,733,677</b>		
<b>05.1 Ordinary Shares (Unquoted): Tk. 127,694,430</b>		
(i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)	12,000,000	12,000,000
(ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)	15,694,430	15,694,430
(iii) Advance to FAM - First Fixed Income Fund	100,000,000	100,000,000
<b>Tk.</b>	<b>127,694,430</b>	<b>127,694,430</b>
<b>05.2 Non-Convertible Zero Coupon Bonds: Tk. 128,262,247</b>		
(i) Brac Bank Ltd.	90,656,550	138,337,500
(ii) IDLC Finance Ltd.	37,605,697	76,574,602
<b>Tk.</b>	<b>128,262,247</b>	<b>214,912,102</b>
<b>05.3 Govt. Securities (Treasury Bills &amp; Bonds)</b>	<b>Tk. 8,295,777,000</b>	<b>2,680,017,000</b>
<b>05.4 Non-Convertible Subordinated Bonds: Tk. 6,600,000,000</b>		
(i) Mutual Trust Bank PLC.	1,600,000,000	1,800,000,000
(ii) Southeast Bank PLC.	200,000,000	300,000,000
(iii) Islami Bank Bangladesh PLC.	200,000,000	300,000,000
(iv) Eastern Bank PLC.	400,000,000	500,000,000
(v) Trust Bank PLC.	200,000,000	300,000,000
(vi) Dutch Bangla Bank PLC.	2,000,000,000	2,000,000,000
(vii) Shahjalal Islami Bank PLC.	1,000,000,000	1,000,000,000
(viii) Prime Bank PLC.	1,000,000,000	1,000,000,000
<b>Tk.</b>	<b>6,600,000,000</b>	<b>7,200,000,000</b>
<b>Tk.</b>	<b>15,151,733,677</b>	<b>10,222,623,532</b>
<b>06. Consolidated Inventories: Tk. 12,912,545,701</b>		
Raw Materials	4,461,421,881	4,447,558,995
Packing Materials	1,372,676,232	1,303,112,558
Work-in-Process	787,765,872	747,716,722
Finished Goods	4,613,181,182	4,480,128,521
Spares & Accessories	1,439,010,654	1,388,998,168
Goods- in-Transit	238,489,880	691,686,667
<b>Tk.</b>	<b>12,912,545,701</b>	<b>13,059,201,630</b>
<b>07. Consolidated Other Receivables: Tk. 2,958,980,329</b>		
Interest Receivable from Fixed Deposit Receipts	2,350,003,347	1,581,777,315
Interest Receivable from Short Notice Deposits	1,205,875	676,679
Gain against Zero Coupon Bonds (Receivable)	40,663,256	58,305,368
Interest Receivable from Subordinated Bonds	63,481,971	63,452,191
Gain/Interest Income from Govt. Securities	343,588,797	879,074
Accrued Income	80,037,083	89,541,141
Insurance Claim Receivable	80,000,000	80,000,000
<b>Tk.</b>	<b>2,958,980,329</b>	<b>1,874,631,768</b>
<b>08. Consolidated Advances, Deposits and Prepayments: Tk. 1,734,407,173</b>		
<b>08.1 Advances: Tk. 1,004,751,589</b>		
Employees	253,850,829	250,355,472
Land Purchase	86,981,900	130,557,871
Suppliers	663,918,860	591,024,247
<b>Tk.</b>	<b>1,004,751,589</b>	<b>971,937,590</b>
<b>08.2 Deposits: Tk. 666,078,926</b>		
Value Added Tax	348,184,574	599,085,253
Earnest Money & Security Deposit	282,311,881	282,082,770
Others	35,582,471	28,737,818
<b>Tk.</b>	<b>666,078,926</b>	<b>909,905,841</b>
<b>08.3 Prepayments: Tk. 63,576,658</b>		
Office Rent	20,960,920	22,845,088
Insurance Premium	42,615,738	90,590,468
<b>Tk.</b>	<b>63,576,658</b>	<b>113,435,556</b>
<b>Tk.</b>	<b>1,734,407,173</b>	<b>1,995,278,987</b>
<b>09. Cash and Cash Equivalents: Tk. 59,665,325,080</b>		
<b>09.1 Cash in Hand</b>	<b>Tk. 5,276,822</b>	<b>4,579,322</b>
<b>09.2 Cash at Bank: Tk. 17,106,516,205</b>		
Current Accounts	851,292,213	686,091,520
STD & SND Accounts	3,408,534,306	15,339,206,722
Export Retention Quota Accounts (held in USD)	279,498,541	230,446,887
Margin Held Accounts (held in USD)	1,703,910,174	1,187,121,736
Dividend Accounts	10,863,280,972	233,445,007
<b>Tk.</b>	<b>17,106,516,205</b>	<b>17,676,311,872</b>
<b>09.3 Fixed Deposit Receipts (FDRs): Tk. 42,553,532,053</b>		
FDRs held in BDT	38,029,112,599	33,655,808,088
FDRs held in USD	4,524,419,454	4,059,607,375
<b>Tk.</b>	<b>42,553,532,053</b>	<b>37,715,415,463</b>
<b>Tk.</b>	<b>59,665,325,080</b>	<b>55,396,306,657</b>
<b>10. Consolidated Retained Earnings: Tk. 130,070,818,605</b>		
Opening Balance	126,893,437,592	114,139,071,906
Add: Net Profit attributable to Equity Holders	14,677,756,485	23,967,971,212
Less: Transferred to Tax Holiday Reserve	(862,963,352)	(1,462,644,416)
Less: Cash Dividend	(10,637,412,120)	(9,750,961,110)
Closing Balance	<b>130,070,818,605</b>	<b>126,893,437,592</b>

	31 Dec 2025	30 Jun 2025
<b>11. Non Controlling Interest: Tk. 7,470,722</b>		
Opening Balance	5,438,329	2,318,478
Add: Net Profit attributable to Non Controlling Interest	2,056,148	3,120,237
Add: Unrealised Gain/(Loss) on Marketable Securities	(23,755)	(386)
Closing Balance	<b>7,470,722</b>	<b>5,438,329</b>
<b>12. Consolidated Loans and Borrowings: Tk. 512,486,309</b>		
Term Loan - Non Current Portion (Note - 12.1)	-	200,000,000
Term Loan - Current Portion (Note - 12.2)	512,486,309	625,501,239
	<b>512,486,309</b>	<b>825,501,239</b>
<b>12.1 Term Loan - Non Current Portion:</b>		
Standard Chartered Bank, Bangladesh	-	200,000,000
	<b>-</b>	<b>200,000,000</b>
<b>12.2 Term Loan - Current Portion: Tk. 512,486,309</b>		
a) Standard Chartered Bank, Kenya	112,486,309	225,501,239
b) Standard Chartered Bank, Bangladesh	400,000,000	400,000,000
	<b>512,486,309</b>	<b>625,501,239</b>
<b>13. Consolidated Deferred Tax Liabilities: Tk. 1,033,761,451</b>		
Deferred Tax - Property, Plant and Equipment:		
a) Square Pharmaceuticals PLC. (Note-13.1a)	533,752,508	571,119,707
b) Square Lifesciences Ltd. (Note-13.1b)	(26,823,683)	(16,233,763)
	506,928,825	554,885,944
Deferred Tax - Income from Investments (Note - 13.2)	620,612,998	370,526,683
Deferred Tax - Marketable Securities (Note-13.3)	(93,780,372)	(89,297,554)
	<b>1,033,761,451</b>	<b>836,115,073</b>
<b>13.1 Deferred Tax - Property, Plant and Equipment:</b>		
<b>a) Square Pharmaceuticals PLC.: Tk. 533,752,508</b>		
Carrying Amount	12,342,804,168	12,351,884,921
Tax Base	9,970,570,797	9,813,575,110
Taxable/(Deductible) Temporary Difference	2,372,233,371	2,538,309,811
Tax Rate	22.50%	22.50%
Closing Liabilities	533,752,508	571,119,707
Opening Liabilities	(571,119,707)	(673,568,392)
Current Period/Year's Expense/(Income)	<b>(37,367,199)</b>	<b>(102,448,685)</b>
<b>b) Square Lifesciences Ltd.: Tk. (26,823,683)</b>		
Carrying Amount	2,472,188,201	2,329,115,167
Tax Base	2,797,323,750	2,624,274,496
Taxable/(Deductible) Temporary Difference	(325,135,549)	(295,159,329)
Tax Rate	8.25%	5.50%
Closing Liabilities	(26,823,683)	(16,233,763)
Opening Liabilities	16,233,763	5,949,954
Current Period/Year's Expense/(Income)	<b>(10,589,920)</b>	<b>(10,283,809)</b>
* Property, plant and equipment excluding Lands, PPE in transit and assets under construction.		
<b>13.2 Deferred Tax - Income from Investments: Tk. 620,612,998</b>		
Carrying Amount	2,758,279,990	1,646,785,259
Tax Base	-	-
Taxable/(Deductible) Temporary Difference	2,758,279,990	1,646,785,259
Tax Rate	22.50%	22.50%
Closing Liabilities	620,612,998	370,526,683
Opening Liabilities	(370,526,683)	-
Current Period/Year's Expense/(Income)	<b>250,086,315</b>	<b>370,526,683</b>
<b>13.3 Deferred Tax - Marketable Securities: Tk. (93,780,372)</b>		
Carrying Amount	10,807,812,506	10,045,505,012
Tax Base	11,433,014,992	10,640,822,033
Taxable/(Deductible) Temporary Difference	(625,202,486)	(595,317,021)
Tax Rate	15.00%	15.00%
Closing Liabilities	(93,780,372)	(89,297,554)
Opening Liabilities	(89,297,554)	(48,536,915)
Current Period/Year's Expense/(Income)	<b>(183,077,926)</b>	<b>(137,834,469)</b>
<b>14. Consolidated Other Payables: Tk. 12,562,700,897</b>		
Sundry Creditors	698,420,410	649,067,541
Income Tax (Deduction at Source)	89,779,284	34,699,694
Retention Money	76,895,865	47,371,869
Dividend Payable	10,637,412,120	-
Workers' Profit Participation Fund and Welfare Fund	1,047,509,522	1,294,939,894
Interest Payable	12,683,696	17,396,209
	<b>12,562,700,897</b>	<b>2,043,475,207</b>
<b>15. Consolidated Current Tax Liabilities: Tk. 1,934,782,269</b>		
Opening balance	1,306,637,831	912,265,905
Provision for the Period/Year	2,759,822,794	4,661,238,463
Tax Paid (including Advance Income Tax) during the Period/Year	(2,131,678,356)	(4,266,866,537)
	<b>1,934,782,269</b>	<b>1,306,637,831</b>
<b>16. Consolidated Accrued Expenses: Tk. 287,016,305</b>		
Accrued Expenses	287,016,305	238,280,139
Audit Fees	-	1,294,944
	<b>287,016,305</b>	<b>239,575,083</b>
<b>17. Consolidated Gross Revenue: Tk. 52,315,611,347</b>		
Square Pharmaceuticals PLC. (Note - 17.2)	39,246,756,551	35,304,007,049
Square Lifesciences Ltd. (Note - 17.3)	12,740,325,880	9,463,710,577
Square Pharmaceuticals Kenya EPZ Ltd. (Note - 17.4)	328,528,916	301,153,992
	<b>52,315,611,347</b>	<b>45,068,871,618</b>



	July'25 - Dec'25	July'24 - Dec'24
<b>17.1 Consolidated Net Revenue: Tk. 43,381,040,302</b>		
Square Pharmaceuticals PLC. (Note - 17.2)	32,812,718,949	29,813,582,142
Square Lifesciences Ltd. (Note - 17.3)	10,239,792,437	7,603,042,538
Square Pharmaceuticals Kenya EPZ Ltd. (Note - 17.4)	328,528,916	301,153,992
<b>Tk.</b>	<b>43,381,040,302</b>	<b>37,717,778,672</b>
<b>17.2 Square Pharmaceuticals PLC.: Tk. 32,812,718,949</b>		
<b>Local:</b>		
Revenue	37,977,740,760	33,911,148,340
Value Added Tax	(4,911,351,315)	(4,378,353,682)
<b>Revenue without VAT</b>	<b>33,066,389,445</b>	<b>29,532,794,658</b>
Discount	(1,522,686,287)	(1,112,071,225)
<b>Net Revenue - Local</b>	<b>31,543,703,158</b>	<b>28,420,723,433</b>
Export - Equivalent to US \$10,351,396 (Jul'24-Dec'24: US \$11,661,087)	1,269,015,791	1,392,858,710
<b>Tk.</b>	<b>32,812,718,949</b>	<b>29,813,582,142</b>
<b>17.3 Square Lifesciences Ltd.: Tk. 10,239,792,437</b>		
<b>Local:</b>		
Revenue	12,723,635,465	9,451,191,757
Value Added Tax	(1,896,469,526)	(1,409,472,442)
<b>Revenue without VAT</b>	<b>10,827,165,939</b>	<b>8,041,719,315</b>
Discount	(604,063,917)	(451,195,597)
<b>Net Revenue - Local</b>	<b>10,223,102,022</b>	<b>7,590,523,718</b>
Export - Equivalent to US \$136,289 (Jul'24-Dec'24: US \$105,155)	16,690,415	12,518,820
<b>Tk.</b>	<b>10,239,792,437</b>	<b>7,603,042,538</b>
<b>17.4 Square Pharmaceuticals Kenya EPZ Ltd.: Tk. 328,528,916</b>		
Local	328,528,916	299,644,126
Export - Equivalent to US \$12,329 in Jul'24-Dec'24	-	1,509,866
<b>Tk.</b>	<b>328,528,916</b>	<b>301,153,992</b>
<b>18. Consolidated Cost of Goods Sold: Tk. 21,837,452,898</b>		
Raw Materials Consumed (Note - 18.1)	9,300,066,561	9,185,208,744
Packing Materials Consumed (Note - 18.2)	4,837,587,724	4,587,058,592
<b>Cost of Materials Consumed</b>	<b>14,137,654,285</b>	<b>13,772,267,336</b>
Manufacturing Overhead (Note - 18.3)	5,978,642,157	5,557,998,552
<b>Total Manufacturing Cost</b>	<b>20,116,296,442</b>	<b>19,330,265,888</b>
Opening Work-in-Process	747,716,722	784,057,550
Closing Work-in-Process	(787,765,872)	(940,413,948)
<b>Cost of Goods Manufactured</b>	<b>20,076,247,292</b>	<b>19,173,909,490</b>
Opening Finished Goods	4,480,128,521	3,825,932,863
Purchase of Finished Goods	2,091,168,276	1,937,318,643
Cost of Physician Sample	(196,910,009)	(142,105,258)
<b>Cost of Goods Available for Sale</b>	<b>26,450,634,080</b>	<b>24,795,055,738</b>
Closing Finished Goods	(4,613,181,182)	(4,901,624,434)
<b>Tk.</b>	<b>21,837,452,898</b>	<b>19,893,431,304</b>
<b>18.1 Consolidated Raw Materials Consumed: Tk. 9,300,066,561</b>		
Opening Stock	4,447,558,996	4,801,972,525
Purchase during the Period	9,313,929,446	9,838,352,155
Closing Stock	(4,461,421,881)	(5,455,115,936)
<b>Tk.</b>	<b>9,300,066,561</b>	<b>9,185,208,744</b>
<b>18.2 Consolidated Packing Materials Consumed: Tk. 4,837,587,724</b>		
Opening Stock	1,303,112,558	1,272,032,952
Purchase during the Period	4,907,151,398	5,008,695,021
Closing Stock	(1,372,676,232)	(1,693,669,381)
<b>Tk.</b>	<b>4,837,587,724</b>	<b>4,587,058,592</b>
<b>18.3 Consolidated Manufacturing Overhead: Tk. 5,978,642,157</b>		
Salaries, Wages & Allowances	1,901,237,042	1,713,533,776
Employer's Contribution to RPF	57,668,517	47,408,850
Contribution to Gratuity Fund	62,840,188	-
Entertainment, Staff Lunch & Refreshments	117,047,926	97,210,332
Recruitment, Training & Development	204,282	636,753
Employees Welfare & Medical Expenses	4,796,922	6,980,623
Staff Uniform	58,949,289	68,417,875
Travelling & Conveyance	58,411,088	34,395,656
US FDA User Fees	134,283,825	82,628,520
Laboratory Consumables	371,815,399	413,135,902
Research & Product Development	77,335,772	192,012,460
Printing & Stationery	49,211,335	48,798,252
Courier, Internet & Telecommunication	4,237,955	5,143,423
Rental Expenses	8,748,088	5,556,495
Power Generation & Purchase	1,110,016,348	867,810,677
Sanitation Expenses	134,529,782	125,497,349
Petrol, Oil & Lubricants	13,611,436	91,932,704
Generator Rental Expenses	5,520,000	18,000,000
Repairs & Maintenance - Factory	340,145,183	301,453,198
Consumption of Spares & Accessories	371,387,895	335,053,833
Repairs & Maintenance - Vehicle	26,818,942	23,327,112
Vehicle Fuel Expenses	36,014,735	34,449,399
Legal & Professional Fees	-	1,138,500
Insurance Premium	36,472,823	34,090,805
Security Services	30,084,261	41,990,553
Govt. Taxes & License Fees	11,024,476	15,800,254
Toll Expenses	122,774,709	81,819,230
Software, Hardware Support & VSAT Services	10,717,148	33,653,217
Depreciation	821,739,697	836,122,804
Other Expenses	997,094	-
<b>Tk.</b>	<b>5,978,642,157</b>	<b>5,557,998,552</b>

	July'25 - Dec'25	July'24 - Dec'24
<b>19. Consolidated Selling and Distribution Expenses: Tk. 7,167,993,428</b>		
Salaries & Allowances	1,071,944,679	938,373,849
Employer's Contribution to RPF	92,295,722	78,042,481
Contribution to Gratuity Fund	121,286,999	-
Entertainment, Staff Lunch & Refreshments	24,636,173	22,240,509
Recruitment, Training & Development	6,043,984	5,838,983
Employees Welfare & Medical Expenses	5,718,471	7,638,814
Staff Uniform	3,914,924	3,518,860
Travelling & Conveyance	84,539,153	89,216,063
Printing & Stationery	46,552,092	49,425,366
Courier, Internet & Telecommunication	49,701,702	49,894,682
Office & Godown Rent	28,125,328	26,412,077
Utilities Expense	29,824,904	25,531,125
Sanitation Expenses	11,240,531	10,897,599
Field Staff Salaries, Allowances, TA & DA	2,219,027,840	1,984,655,468
Target Incentive to Field Staff	391,740,636	243,752,482
Promotional Expenses	589,153,833	563,300,475
Marketing Expenses	857,757,706	607,188,114
Pharmacovigilance	48,931,522	34,073,829
Marketing Website Platform Software Maintenance	10,469,181	7,535,633
Event, Programs & Conference	206,783,337	146,957,044
Literature & Publications	123,043,880	88,184,557
Market Research & Survey Expenses	12,347,940	12,661,447
Advertisement	1,374,570	756,000
Delivery & Packing Expenses	202,175,551	157,344,848
Export Expenses	128,016,904	166,430,399
Free Samples	231,160,947	148,752,556
Repairs & Maintenance - Office	41,090,644	35,899,902
Repairs & Maintenance - Vehicle	120,717,023	115,410,612
Vehicle Fuel Expenses	164,455,539	172,001,031
Insurance Premium	18,391,619	18,001,827
Security Services	62,604,692	56,537,996
Govt. Taxes & License Fees	23,259,754	26,519,661
Bank Charges	8,159,802	8,181,733
Software, Hardware Support & VSAT Services	9,270,823	37,763,617
Depreciation	122,172,662	113,389,371
Other Expenses	62,361	41,897
<b>Tk.</b>	<b>7,167,993,428</b>	<b>6,052,370,907</b>
<b>20. Consolidated Administrative Expenses: Tk. 1,053,154,617</b>		
Salaries & Allowances	323,320,317	290,673,495
Employer's Contribution to RPF	8,442,567	7,482,640
Contribution to Gratuity Fund	15,872,813	-
Directors' Remuneration	49,187,700	44,437,500
Entertainment, Staff Lunch & Refreshments	49,949,670	39,045,477
Recruitment, Training & Development	4,073,515	3,288,068
Employees Welfare & Medical Expenses	9,848,562	6,838,414
Staff Uniform	1,032,761	904,725
Travelling & Conveyance	151,492,975	90,163,957
Printing & Stationery	10,446,977	10,642,980
Courier, Internet & Telecommunication	4,746,331	6,628,549
Office Rent	6,583,711	6,910,370
Utilities Expense	13,191,440	16,995,909
Sanitation Expenses	7,526,848	5,588,248
Fees & Subscription	3,492,631	3,364,900
Legal & Professional Fees	1,170,788	4,006,439
Repairs & Maintenance - Office	120,942,806	103,570,053
Repairs & Maintenance - Vehicle	18,348,511	15,882,479
Vehicle Fuel Expenses	23,937,945	23,805,389
Insurance Premium	23,212,064	18,694,142
Security Services	36,153,948	33,670,507
Audit Fees	143,750	57,500
Statutory Communication Expenses	495,400	448,500
Advertisement	9,780,004	97,800
Govt. Taxes & License Fees	19,224,233	10,667,186
Bank Charges	5,543,866	3,702,559
Software & Hardware Support Services	8,428,624	4,469,501
Depreciation	125,588,760	120,432,032
Other Expenses	975,100	181,838
<b>Tk.</b>	<b>1,053,154,617</b>	<b>872,651,157</b>
<b>21. Consolidated Finance Cost: Tk. 58,071,279</b>		
Square Pharmaceuticals PLC.	-	6,203
Square Lifesciences Ltd.	28,009,708	50,891,574
Square Pharmaceuticals Kenya EPZ Ltd.	30,061,571	76,303,055
<b>Tk.</b>	<b>58,071,279</b>	<b>127,200,832</b>
<b>22. Consolidated Other Operating Income: Tk. 96,185,695</b>		
Rental Income	984,550	987,708
Sale of Scrap	37,087,235	30,972,838
Gain on Fluctuation of Foreign Currency	(2,515,112)	183,778,097
Cash Incentive Received against Export	56,282,265	2,417,200
P.F Forfeiture Amount	703,770	934,049
Gain/(Loss) on Disposal of Property, Plant and Equipment	3,642,987	8,686,642
<b>Tk.</b>	<b>96,185,695</b>	<b>227,776,534</b>

	July'25 - Dec'25	July'24 - Dec'24
<b>23. Consolidated Income from Investments: Tk. 3,620,298,765</b>		
Interest from Deposits	2,263,255,514	1,806,269,044
Interest from Short Notice Deposits	510,143,991	671,593,561
Gain on Redemption of Zero Coupon Bond	8,208,033	17,688,683
Interest from Subordinate Bonds	395,270,602	335,079,562
Dividend Income	96,530,012	127,564,112
Gain/Interest Income from Govt. Securities	342,709,723	-
Gain on Marketable Securities (Realized)	4,180,890	93,192,919
<b>Tk. 3,620,298,765</b>	<b>3,620,298,765</b>	<b>3,051,387,881</b>
<b>24. Consolidated Allocation for WPPF &amp; WF: Tk. 802,569,628</b>		
Square Pharmaceuticals PLC.	578,815,647	500,933,068
Square Lifesciences Ltd.	223,753,981	164,872,029
<b>Tk. 802,569,628</b>	<b>802,569,628</b>	<b>665,805,097</b>
<b>25. Consolidated Income Tax Expense: Tk. 2,961,951,990</b>		
<b>Current Tax Expense:</b>		
Square Pharmaceuticals PLC.	2,386,448,710	2,234,244,820
Square Lifesciences Ltd.	373,374,084	190,557,892
<b>Tk. 2,759,822,794</b>	<b>2,759,822,794</b>	<b>2,424,802,712</b>
<b>Deferred Tax Expense/(Income):</b>		
Square Pharmaceuticals PLC.	212,719,116	(60,647,819)
Square Lifesciences Ltd.	(10,589,920)	(8,252,047)
<b>Tk. 202,129,196</b>	<b>202,129,196</b>	<b>(68,899,866)</b>
<b>Tk. 2,961,951,990</b>	<b>2,961,951,990</b>	<b>2,355,902,846</b>
<b>26. Consolidated Unrealised Gain/(Loss) on Marketable Securities: Tk. (25,402,647)</b>		
Closing Unrealised Gain/(Loss)	(625,202,486)	(174,700,135)
Opening Unrealised Loss/(Gain)	595,317,021	(300,730,028)
	(29,885,465)	126,029,893
	4,482,818	(18,904,484)
<b>Tk. (25,402,647)</b>	<b>(25,402,647)</b>	<b>107,125,409</b>
<b>27. Current Year's Translation Adjustment: Tk. (5,616,435)</b>		
<b>Square Pharmaceuticals Kenya EPZ Ltd.:</b>		
Opening Net Assets	189,998,126	320,935,712
Add: (Profit)/Loss for the Period	(131,087,077)	(70,833,572)
Less: Closing Net Assets	(60,930,272)	(230,853,057)
Translation Adjustment for the Period	<b>(2,019,223)</b>	<b>19,249,082</b>
<b>Samson Pharma Inc.:</b>		
Opening Net Assets	(4,260,858)	-
Add: (Profit)/Loss for the Period	1,195,182	1,451,708
Less: Closing Net Assets	(531,536)	5,999,916
Translation Adjustment for the Period	<b>(3,597,212)</b>	<b>7,451,624</b>
<b>Tk. (5,616,435)</b>	<b>(5,616,435)</b>	<b>26,700,706</b>
<b>28. Consolidated Net Assets Value (NAV) per Share: Tk. 162.41</b>		
Total Assets	161,805,222,744	146,815,407,615
Total Liabilities	(17,838,031,738)	(6,859,598,040)
Net Assets attributable to the Ordinary Shareholders	143,967,191,006	139,955,809,575
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk. 162.41</b>	<b>162.41</b>	<b>157.88</b>
<b>29. Consolidated Earnings per Share (EPS): Tk. 16.56</b>		
Net Profit after Tax attributable to Shareholders	14,676,811,094	12,696,403,058
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk. 16.56</b>	<b>16.56</b>	<b>14.32</b>
<b>30. Consolidated Net Operating Cash Flow (NOCF) per Share: Tk. 13.16</b>		
Net Cash Generated from Operating Activities (Note - 30.1)	11,662,761,260	7,335,508,748
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk. 13.16</b>	<b>13.16</b>	<b>8.28</b>
Last year, revenue growth was restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance. Consequently, both EPS and NOCFPS have recorded notable and healthy growth.		
<b>30.1 Consolidated Reconciliation of Net Profit with Net Cash Generated from Operating Activities:</b>		
<b>Profit for the Period</b>	<b>14,676,811,094</b>	<b>12,696,403,058</b>
Income from Investments (Note - 23)	(3,620,298,765)	(3,056,110,856)
Income Tax Expense	2,961,951,990	2,355,902,846
Adjustments for:		
Non-Cash Income/Expenses:		
Depreciation	1,069,499,843	1,069,944,207
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents	8,131,547	(210,478,803)
Profit from Associate Undertakings	(1,460,480,172)	(1,666,822,114)
Translation Adjustments	(5,616,435)	26,700,706
Gain/(Loss) on Disposal of Property, Plant and Equipment (Note - 22)	(3,642,987)	(8,686,642)
	<b>(392,108,204)</b>	<b>(789,342,646)</b>
Changes in Working Capital:		
(Increase)/Decrease in Current Assets:		
Inventories	146,655,929	(2,010,164,093)
Trade Receivables	(45,232,027)	(16,834,156)
Other Receivables	9,504,058	(89,127)
Advances, Deposits and Prepayments	217,295,843	122,401,204
Increase/(Decrease) in Current Liabilities:		
Trade Payables	(89,395,094)	(130,007,307)
Other Payables	(118,186,430)	251,030,656
Accrued Expenses	47,441,222	(25,566,606)
	<b>168,083,501</b>	<b>(1,809,229,429)</b>
	<b>13,794,439,616</b>	<b>9,397,622,973</b>
Tax Paid	(2,131,678,356)	(2,062,114,225)
<b>Net Cash Generated from Operating Activities</b>	<b>11,662,761,260</b>	<b>7,335,508,748</b>

31. **Consolidated Contingent Liabilities:**  
Liabilities for at Sight Letter of Credit as of 30 December 2025:  
a) Square Pharmaceuticals PLC.: Tk. 8,454,777,731.  
b) Square Lifesciences Ltd.: Tk. 876,293,827.

32. **Related Party Transactions:**

**A. Associates:**

**Square Textiles PLC. (46.36% share):**

Opening Balance  
Addition during the Period  
Realized during the Period  
Closing Balance

	July'25 - Dec'25	July'24 - Dec'24
	-	-
	4,003,040,600	5,386,200,000
	(4,003,040,600)	(5,386,200,000)
Tk.	-	-

**Square Fashions Ltd. (48.63% share):**

Opening Balance  
Addition during the Period  
Realized during the Period  
Closing Balance

	-	-
	2,731,106,913	11,975,938,570
	(2,731,106,913)	(11,975,938,570)
Tk.	-	-

**Square Hospitals Ltd. (49.94% Shares):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance

	-	-
	(25,653,314)	22,759,766
	25,972,814	(22,753,808)
Tk.	319,500	5,958

**B. Subsidiaries of Associates:**

**Square Denims Ltd. (Subsidiary of Square Fashions Ltd.):**

Opening Balance  
Addition during the Period  
Realized during the Period  
Closing Balance

	-	-
	3,222,053,236	840,702,503
	(3,222,053,236)	(840,702,503)
Tk.	-	-

**Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.):**

Opening Balance  
Addition during the Period  
Realized during the Period  
Closing Balance

	-	-
	2,268,918,505	282,037,035
	(2,268,918,505)	(282,037,035)
Tk.	-	-

**C. Others:**

**Square InformatiX Ltd. (Service Provider):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance (Payable)

	(6,833,673)	-
	(42,128,014)	97,160,495
	47,398,234	(97,120,666)
Tk.	(1,563,452)	39,829

**Square Toiletries Ltd. (Supplier):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance (Payable)

	(11,895,085)	-
	(104,998,524)	87,297,553
	116,872,377	(87,281,025)
Tk.	(21,232)	16,528

**Square Food & Beverages Ltd. (Supplier):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance (Payable)

	(11,983,072)	-
	(101,828,804)	81,591,004
	113,811,876	(81,591,004)
Tk.	-	-

**Square Securities Management Ltd. (Port Folio Management):**

Opening Balance  
Addition during the Period  
Realized during the Period  
Closing Balance

	172,412,786	10,659,741
	(29,426,422)	515,198,609
	(61,985,942)	(479,032,337)
Tk.	81,000,422	46,826,013

**Pharma Packages (Pvt.) Ltd. (Supplier):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance

	71,489,278	99,484,237
	(102,355,650)	226,436,116
	94,646,830	(307,596,953)
Tk.	63,780,459	18,323,400

**AEGIS Services Ltd. (Service Provider):**

Opening Balance  
Addition during the Period  
Paid during the Period  
Closing Balance (Payable)

	2,280,690	258,720
	(243,725,205)	243,158,860
	230,076,504	(243,417,580)
Tk.	(11,368,011)	-



# SQUARE PHARMACEUTICALS PLC.

## Statement of Financial Position

As at 31 December 2025

Particulars	Notes	Amounts in Taka	
		31 Dec 2025	30 Jun 2025
<b>ASSETS</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	02	30,786,560,540	27,817,766,671
Investment in Subsidiaries and Associates	03	2,685,852,483	2,624,852,483
Investment in Marketable Securities	04	9,916,793,470	9,471,906,837
Long Term Investment - Others	05	15,151,733,677	10,222,623,532
		<b>58,540,940,170</b>	<b>50,137,149,523</b>
<b>Current Assets:</b>			
Inventories	06	11,223,898,552	11,070,993,435
Trade Receivables	07	2,498,235,523	2,483,411,789
Other Receivables	08	3,254,601,824	2,066,382,484
Advances, Deposits and Prepayments	09	1,657,876,606	1,748,482,902
Cash and Cash Equivalents	10	59,682,047,970	55,444,601,206
		<b>78,316,660,475</b>	<b>72,813,871,816</b>
<b>TOTAL ASSETS</b>		<b>136,857,600,645</b>	<b>122,951,021,339</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY:</b>			
Share Capital		8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
General Reserve		105,878,200	105,878,200
Fair Value Reserve	11	(479,070,373)	(501,177,411)
Retained Earnings	12	98,388,302,806	100,048,569,815
<b>TOTAL EQUITY</b>		<b>108,915,085,733</b>	<b>110,553,245,704</b>
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities:</b>			
Deferred Tax Liabilities	13	1,069,823,676	853,203,317
		<b>1,069,823,676</b>	<b>853,203,317</b>
<b>Current Liabilities:</b>			
Trade Payables		748,894,191	637,522,743
Other Payables	14	23,933,851,052	9,269,696,574
Current Tax Liabilities	15	1,684,927,653	1,165,586,075
Accrued Expenses	16	283,187,340	238,321,920
Unclaimed Dividend	17	221,831,000	233,445,006
		<b>26,872,691,236</b>	<b>11,544,572,318</b>
<b>TOTAL LIABILITIES</b>		<b>27,942,514,912</b>	<b>12,397,775,635</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>136,857,600,645</b>	<b>122,951,021,339</b>
<b>Net Assets Value (NAV) per Share</b>	26	<b>122.87</b>	<b>124.71</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

## Statement of Profit or Loss and Other Comprehensive Income For the Six-month Period Ended 31 December 2025

Particulars	Notes	Six-month period		2nd Quarter	
		July'25 - Dec'25	July'24 - Dec'24	Oct'25 - Dec'25	Oct'24 - Dec'24
<b>Net Revenue</b>	18	33,230,787,657	29,896,175,660	16,837,716,067	15,879,308,873
Cost of Goods Sold	19	(18,710,634,228)	(17,308,352,978)	(10,068,021,039)	(9,728,323,206)
<b>Gross Profit</b>		<b>14,520,153,429</b>	<b>12,587,822,682</b>	<b>6,769,695,028</b>	<b>6,150,985,667</b>
Selling and Distribution Expenses	20	(7,021,533,001)	(5,961,459,241)	(3,416,164,013)	(2,944,044,994)
Administrative Expenses	21	(1,045,825,156)	(869,579,561)	(503,174,167)	(434,694,427)
Finance Cost		-	(6,203)	-	(6,203)
<b>Operating Expenses</b>		<b>(8,067,358,157)</b>	<b>(6,831,045,005)</b>	<b>(3,919,338,180)</b>	<b>(3,378,745,624)</b>
<b>Profit before Other Operating Income</b>		<b>6,452,795,272</b>	<b>5,756,777,677</b>	<b>2,850,356,848</b>	<b>2,772,240,043</b>
Other Operating Income	22	2,095,985,049	1,713,803,860	1,076,319,719	798,650,467
<b>Profit from Operations</b>		<b>8,548,780,321</b>	<b>7,470,581,537</b>	<b>3,926,676,567</b>	<b>3,570,890,510</b>
Income from Investments	23	3,606,348,263	3,049,012,881	1,869,089,888	1,588,212,236
<b>Profit before contribution to WPPF &amp; WWF</b>		<b>12,155,128,584</b>	<b>10,519,594,418</b>	<b>5,795,766,455</b>	<b>5,159,102,746</b>
Contribution to WPPF & WWF		(578,815,647)	(500,933,068)	(275,988,879)	(245,671,560)
<b>Profit before Tax</b>		<b>11,576,312,937</b>	<b>10,018,661,350</b>	<b>5,519,777,576</b>	<b>4,913,431,186</b>
Current Tax (Expense)		(2,386,448,710)	(2,234,244,820)	(1,176,829,567)	(1,115,747,951)
Deferred Tax (Expense) / Income		(212,719,116)	60,647,819	(61,668,178)	28,290,151
<b>Income Tax Expense</b>	24	<b>(2,599,167,826)</b>	<b>(2,173,597,001)</b>	<b>(1,238,497,745)</b>	<b>(1,087,457,800)</b>
<b>Profit after Tax</b>		<b>8,977,145,111</b>	<b>7,845,064,349</b>	<b>4,281,279,831</b>	<b>3,825,973,386</b>
Unrealised Gain/(Loss) on Marketable Securities	25	26,008,281	139,305,006	(1,241,287,548)	(692,655,629)
Deferred Tax (Expense) / Income		(3,901,243)	(20,895,751)	186,193,132	103,898,344
<b>Other Comprehensive Income</b>		<b>22,107,038</b>	<b>118,409,255</b>	<b>(1,055,094,416)</b>	<b>(588,757,285)</b>
<b>Total Comprehensive Income</b>		<b>8,999,252,149</b>	<b>7,963,473,604</b>	<b>3,226,185,415</b>	<b>3,237,216,101</b>
<b>Earnings per Share (EPS)</b>	27	<b>10.13</b>	<b>8.85</b>	<b>4.83</b>	<b>4.32</b>

The annexed notes form an integral part of these financial statements.

Sd/-

Samuel S Chowdhury  
Chairman

Sd/-

Mrs. Ratna Patra  
Vice-Chairman

Sd/-

Tapan Chowdhury  
Managing Director

Sd/-

Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-

Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

## Statement of Changes in Equity For the Six-month Period Ended 31 December 2025

Amounts in Taka

Particulars	Share Capital	Share Premium	General Reserve	Fair Value Reserve	Retained Earnings	Total
<b>As At 01 July 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(270,973,443)</b>	<b>95,060,239,763</b>	<b>105,795,119,620</b>
Profit after Tax	-	-	-	-	7,845,064,349	7,845,064,349
Other Comprehensive Income	-	-	-	118,409,255	-	118,409,255
Cash Dividend (2023-24)	-	-	-	-	(9,750,961,110)	(9,750,961,110)
<b>As At 31 December 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(152,564,188)</b>	<b>93,154,343,002</b>	<b>104,007,632,114</b>
<b>As At 01 July 2025</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(501,177,411)</b>	<b>100,048,569,815</b>	<b>110,553,245,704</b>
Profit after Tax	-	-	-	-	8,977,145,111	8,977,145,111
Other Comprehensive Income	-	-	-	22,107,038	-	22,107,038
Cash Dividend (2024-25)	-	-	-	-	(10,637,412,120)	(10,637,412,120)
<b>As At 31 December 2025</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(479,070,373)</b>	<b>98,388,302,806</b>	<b>108,915,085,733</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary





# SQUARE PHARMACEUTICALS PLC.

## Statement of Cash Flows For the Six-month Period Ended 31 December 2025

			Amounts in Taka
Particulars	Notes	July'25 - Dec'25	July'24 - Dec'24
<b>Cash Flows from Operating Activities:</b>			
Receipts from Customers		38,127,315,238	34,062,799,865
Receipts from Others		2,000,842,751	1,520,557,780
Payments to Suppliers		(13,521,079,958)	(13,608,261,896)
Payments for Manufacturing and Operating Expenses		(12,370,097,046)	(10,951,660,475)
Payment of Value Added Tax		(4,838,969,655)	(4,320,367,894)
<b>Cash Generated from Operations</b>		<b>9,398,011,330</b>	<b>6,703,067,380</b>
Interest Paid		-	(6,203)
Payment of Income Tax		(1,867,107,132)	(1,766,599,863)
Payment of WPPF & WF		(1,050,000,000)	(536,159,925)
Others		4,403,505,582	2,257,179,456
<b>Net Cash Generated from Operating Activities</b>	28	<b>10,884,409,780</b>	<b>6,657,480,845</b>
<b>Cash Flows from Investing Activities:</b>			
Purchase of Property, Plant and Equipment		(3,752,026,631)	(3,233,956,113)
Proceeds from Sale of Property, Plant and Equipment		16,037,884	22,309,355
Investment in Subsidiaries and Associates		(61,000,000)	-
Long Term Investment - Others		(4,929,110,145)	(540,102,706)
Investment in Marketable Securities		(414,967,964)	(263,310,097)
Interest Received		2,425,735,244	2,708,416,424
Dividends Received	23	82,850,012	125,189,112
<b>Net Cash from/(Used in) Investing Activities</b>		<b>(6,632,481,600)</b>	<b>(1,181,454,025)</b>
<b>Cash Flows from Financing Activities:</b>			
Payment of Dividend for preceding years		(11,614,006)	(5,871,856)
<b>Net Cash Used in Financing Activities</b>		<b>(11,614,006)</b>	<b>(5,871,856)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>		<b>4,240,314,174</b>	<b>5,470,154,964</b>
Cash and Cash Equivalents at 01 July	10	55,444,601,206	52,305,603,356
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents		(2,867,410)	184,149,451
<b>Cash and Cash Equivalents at 31 December</b>	10	<b>59,682,047,970</b>	<b>57,959,907,771</b>
<b>Net Operating Cash Flow (NOCF) per Share</b>	28	<b>12.28</b>	<b>7.51</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



**SQUARE PHARMACEUTICALS PLC.****Notes to the Financial Statements****As at and For the Six-month Period Ended 31 December 2025****01. Basis of Preparation of the Interim Financial Statements:**

These Financial Statements are the unaudited Interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913, for the 2nd Quarter ended on December 31, 2025. These are prepared in accordance with the International Accounting Standard (IAS-34) 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2025, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below. Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understand that the business is growing every year meaning the assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if those assets are disposed at the date of financial reporting. But at present, the management has no intention to dispose these assets. Therefore, it is not required to record the impairment gain as provisions of IAS-36.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

There is no significant event after the end of the interim period that has to be reflected in these financial statements for the interim period.

**02. Property, Plant and Equipment: Tk. 30,786,560,540****Cost:**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**Accumulated Depreciation:**

Opening Balance

Charged for the Period/Year

Disposal/Transfer during the Period/Year

**Net Book Value**

Property, Plant and Equipment in Transit (Note - 02.1)

Capital Work-in-Progress (Note - 02.2)

**02.1 Property, Plant and Equipment in Transit: Tk. 608,712,452**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**02.2 Capital Work-in-Progress: Tk. 8,542,424,609****02.2.1 Building and Other Constructions: Tk. 4,593,493,174**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**02.2.2 Plant & Machinery: Tk. 3,948,931,435**

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

**03. Investment in Subsidiaries and Associates: Tk. 2,685,852,483****03.1 Subsidiaries: Tk. 2,098,772,688**

(i) Square Pharmaceuticals Kenya EPZ Ltd. (8,000,000 Ordinary Shares plus Share Money Deposit)

(ii) Square Lifesciences Ltd., Bangladesh (9,995,000 Ordinary Shares)

(iii) Samson Pharma Inc., The Philippines (139,998 Ordinary Shares)

**03.2 Associates: Tk. 587,079,795**

(i) Square Textiles PLC. (91,436,677 Ordinary Shares of Tk. 10/- each including Bonus Shares)

(ii) Square Hospitals Ltd. (199,750 Ordinary Shares of Tk. 1,000/- each plus Share Premium)

(iii) Square Fashions Ltd. (462,000 Ordinary Shares of Tk. 100/- each plus Share Premium)

	31 Dec 2025	30 Jun 2025
	47,429,596,684	45,591,709,620
	1,260,208,494	2,008,355,765
	48,689,805,178	47,600,065,385
	(54,144,720)	(170,468,701)
<b>Tk.</b>	<b>48,635,660,458</b>	<b>47,429,596,684</b>
	26,227,572,966	24,687,303,495
	814,413,836	1,655,261,555
	27,041,986,802	26,342,565,050
	(41,749,823)	(114,992,084)
<b>Tk.</b>	<b>27,000,236,979</b>	<b>26,227,572,966</b>
	21,635,423,479	21,202,023,718
	608,712,452	977,407,195
	8,542,424,609	5,638,335,758
<b>Tk.</b>	<b>30,786,560,540</b>	<b>27,817,766,671</b>
	977,407,195	977,165,568
	1,082,251,293	1,258,540,302
	2,059,658,488	2,235,705,870
	(1,450,946,036)	(1,258,298,675)
<b>Tk.</b>	<b>608,712,452</b>	<b>977,407,195</b>
	2,983,003,892	1,317,735,384
	1,610,489,282	1,833,001,113
	4,593,493,174	3,150,736,497
	-	(167,732,605)
<b>Tk.</b>	<b>4,593,493,174</b>	<b>2,983,003,892</b>
	2,655,331,866	455,849,227
	1,293,599,569	2,200,184,173
	3,948,931,435	2,656,033,400
	-	(701,534)
<b>Tk.</b>	<b>3,948,931,435</b>	<b>2,655,331,866</b>
<b>Tk.</b>	<b>8,542,424,609</b>	<b>5,638,335,758</b>
	985,742,688	985,742,688
	999,500,000	999,500,000
	113,530,000	52,530,000
<b>Tk.</b>	<b>2,098,772,688</b>	<b>2,037,772,688</b>
	225,129,795	225,129,795
	210,750,000	210,750,000
	151,200,000	151,200,000
<b>Tk.</b>	<b>587,079,795</b>	<b>587,079,795</b>
<b>Tk.</b>	<b>2,685,852,483</b>	<b>2,624,852,483</b>

	31 Dec 2025	30 Jun 2025
<b>04. Investment in Marketable Securities: Tk. 9,916,793,470</b>		
<b>04.1 Cost: Tk. 10,480,405,673</b>		
Opening Balance	10,061,527,321	9,320,504,933
Addition during the Period/Year	508,585,792	890,923,381
Sold during the Period/Year	(89,707,440)	(149,900,993)
<b>Tk.</b>	<b>10,480,405,673</b>	<b>10,061,527,321</b>
<b>04.2 Market Value: Tk. 9,916,793,470</b>		
Opening Balance	9,471,906,837	9,001,712,647
Addition during the Period/Year	538,504,461	751,600,998
Sold during the Period/Year	(93,617,828)	(281,406,808)
<b>Tk.</b>	<b>9,916,793,470</b>	<b>9,471,906,837</b>
<b>05. Long Term Investment - Others: Tk. 15,151,733,677</b>		
<b>05.1 Ordinary Shares (Unquoted): Tk. 127,694,430</b>		
(i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)	12,000,000	12,000,000
(ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)	15,694,430	15,694,430
(iii) Advance to FAM - First Fixed Income Fund	100,000,000	100,000,000
<b>Tk.</b>	<b>127,694,430</b>	<b>127,694,430</b>
<b>05.2 Non-Convertible Subordinated Bonds: Tk. 6,600,000,000</b>		
(i) Mutual Trust Bank PLC.	1,600,000,000	1,800,000,000
(ii) Southeast Bank PLC.	200,000,000	300,000,000
(iii) Islami Bank Bangladesh PLC.	200,000,000	300,000,000
(iv) Eastern Bank PLC.	400,000,000	500,000,000
(v) Trust Bank PLC.	200,000,000	300,000,000
(vi) Dutch Bangla Bank PLC.	2,000,000,000	2,000,000,000
(vii) Shahjalal Islami Bank PLC.	1,000,000,000	1,000,000,000
(viii) Prime Bank PLC.	1,000,000,000	1,000,000,000
<b>Tk.</b>	<b>6,600,000,000</b>	<b>7,200,000,000</b>
<b>05.3 Govt. Securities (Treasury Bills &amp; Bonds)</b>	<b>Tk. 8,295,777,000</b>	<b>2,680,017,000</b>
<b>05.4 Non-Convertible Zero Coupon Bonds: Tk. 128,262,247</b>		
(i) Brac Bank PLC.	90,656,550	138,337,500
(ii) IDLC Finance PLC.	37,605,697	76,574,602
<b>Tk.</b>	<b>128,262,247</b>	<b>214,912,102</b>
<b>Tk.</b>	<b>15,151,733,677</b>	<b>10,222,623,532</b>
<b>06. Inventories: Tk. 11,223,898,552</b>		
Raw Materials	4,033,935,387	3,842,166,548
Packing Materials	1,189,851,008	1,142,841,298
Work-in-Process	667,720,841	640,780,824
Finished Goods	3,826,202,602	3,647,257,796
Spares & Accessories	1,267,698,834	1,237,756,627
Goods- in-Transit	238,489,880	560,190,342
<b>Tk.</b>	<b>11,223,898,552</b>	<b>11,070,993,435</b>
<b>07. Trade Receivables:</b>	<b>Tk. 2,498,235,523</b>	<b>2,483,411,789</b>
<b>08. Other Receivables: Tk. 3,254,601,824</b>		
Interest Receivable from Fixed Deposit Receipts	2,350,003,347	1,581,777,315
Interest Receivable from Short Notice Deposits	1,205,875	676,679
Gain against Zero Coupon Bonds (Receivable)	40,663,256	58,305,368
Interest Receivable from Subordinated Bonds	63,481,971	63,452,191
Gain/Interest Income from Govt. Securities	343,588,797	879,074
Accrued Income	375,658,578	281,291,857
Insurance Claim Receivable	80,000,000	80,000,000
<b>Tk.</b>	<b>3,254,601,824</b>	<b>2,066,382,484</b>
<b>09. Advances, Deposits and Prepayments: Tk. 1,657,876,606</b>		
<b>09.1 Advances: Tk. 987,579,265</b>		
Employees	253,850,829	250,355,472
Land Purchase	86,981,900	130,557,871
Suppliers	646,746,537	585,869,673
<b>Tk.</b>	<b>987,579,265</b>	<b>966,783,016</b>
<b>09.2 Deposits: Tk. 611,645,583</b>		
Value Added Tax	295,811,623	368,193,283
Earnest Money & Security Deposit	280,251,489	280,820,533
Others	35,582,471	28,737,818
<b>Tk.</b>	<b>611,645,583</b>	<b>677,751,634</b>
<b>09.3 Prepayments: Tk. 58,651,758</b>		
Office Rent	20,595,420	22,476,585
Insurance Premium	38,056,338	81,471,668
<b>Tk.</b>	<b>58,651,758</b>	<b>103,948,253</b>
<b>Tk.</b>	<b>1,657,876,606</b>	<b>1,748,482,902</b>
<b>10. Cash and Cash Equivalents: Tk. 59,682,047,970</b>		
<b>10.1 Cash in Hand</b>	<b>Tk. 5,195,728</b>	<b>4,559,644</b>
<b>10.2 Cash at Bank: Tk. 17,123,320,189</b>		
Current Accounts	909,995,895	746,755,203
STD & SND Accounts	3,408,534,306	15,339,206,722
Export Retention Quota Accounts (held in USD)	268,728,523	224,189,392
Margin Held Accounts (held in USD)	1,672,780,494	1,181,029,775
Dividend Accounts	10,863,280,972	233,445,007
<b>Tk.</b>	<b>17,123,320,189</b>	<b>17,724,626,099</b>

	31 Dec 2025	30 Jun 2025
<b>10.3 Fixed Deposit Receipts (FDRs): Tk. 42,553,532,053</b>		
FDRs held in BDT	38,029,112,599	33,250,395,536
FDRs held in USD	4,524,419,454	4,465,019,927
<b>Tk. 42,553,532,053</b>	<b>37,715,415,463</b>	
<b>Tk. 59,682,047,970</b>	<b>55,444,601,206</b>	
<b>11. Fair Value Reserve: Tk. (479,070,373)</b>		
Opening Balance	(501,177,411)	(270,973,443)
Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 25)	26,008,281	(270,828,198)
Current Period's/Year's Deferred Tax (Expense)/Income (Note - 13.3)	(3,901,243)	40,624,230
<b>Tk. (479,070,373)</b>	<b>(501,177,411)</b>	
<b>12. Retained Earnings: Tk. 98,388,302,806</b>		
Opening Balance	100,048,569,815	95,060,239,763
Profit after Tax	8,977,145,111	14,739,291,162
Cash Dividend	(10,637,412,120)	(9,750,961,110)
<b>Tk. 98,388,302,806</b>	<b>100,048,569,815</b>	
<b>13. Deferred Tax Liabilities: Tk. 1,069,823,676</b>		
Deferred Tax - Property, Plant and Equipment (Note - 13.1)	533,752,508	571,119,707
Deferred Tax - Income from Investments (Note - 13.2)	620,612,998	370,526,683
Deferred Tax - Marketable Securities (Note - 13.3)	(84,541,830)	(88,443,073)
<b>Tk. 1,069,823,676</b>	<b>853,203,317</b>	
<b>13.1 Deferred Tax - Property, Plant and Equipment: Tk. 533,752,508</b>		
Carrying Amount	12,342,804,168	12,351,884,921
Tax Base	9,970,570,797	9,813,575,110
Taxable/(Deductible) Temporary Difference	2,372,233,371	2,538,309,811
Tax Rate	22.50%	22.50%
Closing Liability	533,752,508	571,119,707
Opening Liability	(571,119,707)	(673,568,392)
Current Period's/Year's Expense/(Income)	<b>(37,367,199)</b>	<b>(102,448,685)</b>
* Property, plant and equipment excluding lands, PPE in transit and assets under construction.		
<b>13.2 Deferred Tax - Other Receivables: Tk. 620,612,998</b>		
Carrying Amount	2,758,279,990	1,646,785,259
Tax Base	-	-
Taxable/(Deductible) Temporary Difference	2,758,279,990	1,646,785,259
Tax Rate	22.50%	22.50%
Closing Liability	620,612,998	370,526,683
Opening Liability	(370,526,683)	-
Current Period's/Year's Expense/(Income)	<b>250,086,315</b>	<b>370,526,683</b>
<b>13.3 Deferred Tax - Marketable Securities: Tk. (84,541,830)</b>		
Carrying Amount	9,916,793,470	9,471,906,837
Tax Base	10,480,405,673	10,061,527,321
Taxable/(Deductible) Temporary Difference	(563,612,203)	(589,620,484)
Tax Rate	15.00%	15.00%
Closing Liability	(84,541,830)	(88,443,073)
Opening Liability	88,443,073	47,818,843
Current Period's/Year's Expense/(Income)	<b>3,901,243</b>	<b>(40,624,230)</b>
<b>14. Other Payables: Tk. 23,933,851,052</b>		
Sundry Creditors	12,760,173,430	8,286,228,256
Income Tax (Deduction at Source)	15,178,233	8,382,382
Retention Money	27,448,036	10,262,350
Dividend Payable	10,637,412,120	-
Workers' Profit Participation Fund and Welfare Fund	493,639,233	964,823,586
<b>Tk. 23,933,851,052</b>	<b>9,269,696,574</b>	
<b>15. Current Tax Liabilities: Tk. 1,684,927,653</b>		
Opening Balance	1,165,586,075	912,265,905
Provision made for the Period/Year	2,386,448,710	4,289,102,568
Payment made during the Period/Year	(1,867,107,132)	(4,035,782,398)
<b>Tk. 1,684,927,653</b>	<b>1,165,586,075</b>	
<b>16. Accrued Expenses: Tk. 283,187,340</b>		
Accrued Expenses	283,187,340	237,221,920
Audit Fees	-	1,100,000
<b>Tk. 283,187,340</b>	<b>238,321,920</b>	
<b>17. Unclaimed Dividend: Tk. 221,831,000</b>		
Opening Balance	233,445,006	191,983,629
Addition during the Period/Year	-	99,302,498
Paid to shareholders during the Period/Year	(11,614,006)	(8,737,779)
Transferred to CMS Fund during the Period/Year	-	(49,103,342)
<b>Tk. 221,831,000</b>	<b>233,445,006</b>	

	July'25 - Dec'25	July'24 - Dec'24
<b>18. Gross Revenue: Tk. 39,664,825,259</b>		
Local	38,395,809,468	33,993,741,858
Export	1,269,015,791	1,392,858,710
<b>Tk. 39,664,825,259</b>	<b>39,664,825,259</b>	<b>35,386,600,567</b>
<b>18.1 Net Revenue: Tk. 33,230,787,657</b>		
<b>Local:</b>		
Revenue	38,395,809,468	33,993,741,858
Value Added Tax	(4,911,351,315)	(4,378,353,682)
<b>Revenue without VAT</b>	<b>33,484,458,153</b>	<b>29,615,388,176</b>
Discount	(1,522,686,287)	(1,112,071,225)
<b>Net Revenue - Local</b>	<b>31,961,771,866</b>	<b>28,503,316,951</b>
Export - Equivalent to US \$10,351,396 (Jul'24-Dec'24: US \$11,661,087)	1,269,015,791	1,392,858,710
<b>Tk. 33,230,787,657</b>	<b>33,230,787,657</b>	<b>29,896,175,660</b>
<b>19. Cost of Goods Sold: Tk. 18,710,634,228</b>		
Raw Materials Consumed (Note - 19.1)	7,714,283,969	7,369,307,698
Packing Materials Consumed (Note - 19.2)	4,057,011,304	3,874,825,721
<b>Cost of Materials Consumed</b>	<b>11,771,295,274</b>	<b>11,244,133,419</b>
Add: Manufacturing Overhead (Note - 19.3)	5,207,990,385	4,774,670,118
<b>Total Manufacturing Cost</b>	<b>16,979,285,659</b>	<b>16,018,803,537</b>
Add: Opening Work-in-Process	640,780,824	582,783,730
Less: Closing Work-in-Process	(667,720,841)	(669,632,733)
<b>Cost of Goods Manufactured</b>	<b>16,952,345,642</b>	<b>15,931,954,534</b>
Add: Opening Finished Goods	3,647,257,796	3,531,153,695
Add: Purchase of Finished Goods	2,091,168,276	1,937,318,643
Less: Physician Samples	(153,934,884)	(110,549,689)
<b>Cost of Goods Available for Sale</b>	<b>22,536,836,830</b>	<b>21,289,877,183</b>
Less: Closing Finished Goods	(3,826,202,602)	(3,981,524,205)
<b>Tk. 18,710,634,228</b>	<b>18,710,634,228</b>	<b>17,308,352,978</b>
<b>19.1 Raw Materials Consumed: Tk. 7,714,283,969</b>		
Opening Stock	3,842,166,548	3,722,861,831
Purchased during the Period	7,906,052,808	8,034,163,286
Closing Stock	(4,033,935,387)	(4,387,717,419)
<b>Tk. 7,714,283,969</b>	<b>7,714,283,969</b>	<b>7,369,307,698</b>
<b>19.2 Packing Materials Consumed: Tk. 4,057,011,304</b>		
Opening Stock	1,142,841,298	1,091,402,281
Purchased during the Period	4,104,021,014	4,111,745,608
Closing Stock	(1,189,851,008)	(1,328,322,168)
<b>Tk. 4,057,011,304</b>	<b>4,057,011,304</b>	<b>3,874,825,721</b>
<b>19.3 Manufacturing Overhead: Tk. 5,207,990,385</b>		
Salaries, Wages & Allowances	1,754,862,341	1,582,369,117
Employer's Contribution to RPF	57,668,517	47,408,850
Contribution to Gratuity Fund	62,840,188	-
Entertainment, Staff Lunch & Refreshments	113,481,980	91,190,524
Recruitment, Training & Development	204,282	636,753
Employees Welfare & Medical Expenses	4,796,922	6,980,623
Staff Uniform	56,598,355	58,913,847
Travelling & Conveyance	54,970,108	31,392,277
US FDA User Fees	134,283,825	82,628,520
Laboratory Consumables	325,824,070	342,875,259
Research & Product Development	73,277,229	186,586,709
Printing & Stationery	45,651,864	45,414,117
Courier, Internet & Telecommunication	4,231,955	5,137,423
Rental Expenses	1,308,102	649,710
Power Generation & Purchase	927,658,989	749,281,335
Sanitation Expenses	113,882,938	107,738,866
Petrol, Oil & Lubricants	6,552,047	7,038,470
Generator Rental Expenses	5,520,000	18,000,000
Repairs & Maintenance - Factory	275,606,801	251,532,259
Consumption of Spares & Accessories	356,524,639	335,053,833
Repairs & Maintenance - Vehicle	26,818,942	23,327,112
Vehicle Fuel Expenses	36,014,735	34,449,399
Legal & Professional Fees	-	1,138,500
Insurance Premium	28,465,383	25,204,440
Security Services	30,084,261	41,990,553
Govt. Taxes & License Fees	10,811,956	15,043,055
Toll Expenses	122,774,709	81,819,230
Software, Hardware Support & VSAT Services	10,527,602	33,577,747
Depreciation	566,747,645	567,291,590
<b>Tk. 5,207,990,385</b>	<b>5,207,990,385</b>	<b>4,774,670,118</b>

	July'25 - Dec'25	July'24 - Dec'24
<b>20. Selling and Distribution Expenses: Tk. 7,021,533,001</b>		
Salaries & Allowances	1,071,097,073	937,599,378
Employer's Contribution to RPF	92,295,722	78,042,481
Contribution to Gratuity Fund	121,286,999	-
Entertainment, Staff Lunch & Refreshments	24,636,173	22,240,509
Recruitment, Training & Development	6,043,984	5,838,983
Employees Welfare & Medical Expenses	5,718,471	7,638,814
Staff Uniform	3,914,924	3,518,860
Travelling & Conveyance	84,539,153	89,216,063
Printing & Stationery	46,552,092	49,425,366
Courier, Internet & Telecommunication	49,701,702	49,894,682
Office & Godown Rent	28,125,328	26,412,077
Utilities Expense	29,824,904	25,531,125
Sanitation Expenses	11,240,531	10,897,599
Field Staff Salaries, Allowances, TA & DA	2,161,861,644	1,947,780,246
Target Incentive to Field Staff	373,882,254	233,992,009
Promotional Expenses	589,153,833	563,300,475
Marketing Expenses	857,757,706	607,188,114
Pharmacovigilance	48,931,522	34,073,829
Marketing Website Platform Software Maintenance	10,469,181	7,535,633
Event, Programs & Conference	206,783,337	146,957,044
Literature & Publications	123,043,880	88,184,557
Market Research & Survey Expenses	12,347,940	12,661,447
Advertisement	1,374,570	756,000
Delivery & Packing Expenses	185,838,623	152,594,665
Export Expenses	127,901,419	165,881,949
Free Samples	177,025,117	110,549,689
Repairs & Maintenance - Office	41,090,644	35,899,902
Repairs & Maintenance - Vehicle	120,717,023	115,410,612
Vehicle Fuel Expenses	164,455,539	172,001,031
Insurance Premium	18,391,619	18,001,827
Security Services	62,604,692	56,537,996
Govt. Taxes & License Fees	23,259,754	26,519,661
Bank Charges	8,159,802	8,181,733
Software, Hardware Support & VSAT Services	9,270,823	37,763,617
Depreciation	122,172,662	113,389,371
Other Expenses	62,361	41,897
<b>Tk.</b>	<b>7,021,533,001</b>	<b>5,961,459,241</b>
<b>21. Administrative Expenses: Tk. 1,045,825,156</b>		
Salaries & Allowances	319,138,850	289,235,193
Employer's Contribution to RPF	8,442,567	7,482,640
Contribution to Gratuity Fund	15,872,813	-
Directors' Remuneration	49,187,700	44,437,500
Entertainment, Staff Lunch & Refreshments	49,949,670	39,045,477
Recruitment, Training & Development	4,073,515	3,288,068
Employees Welfare & Medical Expenses	9,848,562	6,838,414
Staff Uniform	1,032,761	904,725
Travelling & Conveyance	151,492,519	90,163,957
Printing & Stationery	10,368,929	10,642,980
Courier, Internet & Telecommunication	4,735,763	6,628,549
Office Rent	5,654,088	5,654,088
Utilities Expense	13,191,440	16,995,909
Sanitation Expenses	7,526,848	5,588,248
Fees & Subscription	3,492,631	3,364,900
Legal & Professional Fees	829,136	3,840,167
Repairs & Maintenance - Office	120,934,981	103,545,407
Repairs & Maintenance - Vehicle	18,348,511	15,882,479
Vehicle Fuel Expenses	23,937,945	23,805,389
Insurance Premium	23,212,064	18,694,142
Security Services	36,153,948	33,670,507
Audit Fees	143,750	57,500
Statutory Communication Expenses	495,400	448,500
Advertisement	9,780,004	97,800
Govt. Taxes & License Fees	18,596,090	10,549,060
Bank Charges	5,318,071	3,634,591
Software & Hardware Support Services	8,428,624	4,469,501
Depreciation	125,493,529	120,432,032
Other Expenses	144,447	181,838
<b>Tk.</b>	<b>1,045,825,156</b>	<b>869,579,561</b>
<b>22. Other Operating Income: Tk. 2,095,985,049</b>		
Rental Income	8,184,550	8,187,708
Sale of Scrap	37,087,236	30,972,838
Gain/(Loss) on Fluctuation of Foreign Currency	(2,867,410)	184,149,451
Cash Incentive Received against Export	56,282,265	2,417,200
Commission Received	1,992,951,651	1,478,455,972
P.F Forfeiture Amount	703,770	934,049
Gain/(Loss) on Disposal of Property, Plant and Equipment	3,642,987	8,686,642
<b>Tk.</b>	<b>2,095,985,049</b>	<b>1,713,803,860</b>

	July'25 - Dec'25	July'24 - Dec'24																																				
<b>23. Income from Investments: Tk. 3,606,348,263</b>																																						
Interest from Deposits	2,263,255,514	1,806,269,044																																				
Interest from Short Notice Deposits	510,143,991	671,593,561																																				
Gain on Redemption of Zero Coupon Bond	8,208,033	17,688,683																																				
Interest from Subordinate Bonds	395,270,602	335,079,562																																				
Dividend Income	82,850,012	125,189,112																																				
Gain/Interest Income from Govt. Securities	342,709,723	-																																				
Gain on Sale of Marketable Securities (Realized)	3,910,388	93,192,919																																				
<b>Tk.</b>	<b>3,606,348,263</b>	<b>3,049,012,881</b>																																				
<b>24. Income Tax Expenses: Tk. 2,599,167,826</b>																																						
Current Tax Expense	2,386,448,710	2,234,244,820																																				
Deferred Tax Expense / (Income)	212,719,116	(60,647,819)																																				
<b>Tk.</b>	<b>2,599,167,826</b>	<b>2,173,597,001</b>																																				
<b>24.1 Reconciliation of Effective Tax Rate:</b>																																						
	<table> <tr> <th></th><th>July'25 - Dec'25</th><th>July'24 - Dec'24</th></tr> <tr> <td></td><td>% Taka</td><td>% Taka</td></tr> <tr> <td>Profit before Tax</td><td>11,576,312,937</td><td>10,018,661,350</td></tr> <tr> <td>Income Tax using Corporate Tax Rate</td><td>22.50% 2,604,670,411</td><td>22.50% 2,254,198,804</td></tr> <tr> <td>Effects of:</td><td></td><td></td></tr> <tr> <td>Income Exempted from Tax</td><td>0.01% 769,510</td><td>-0.45% (45,413,580)</td></tr> <tr> <td>Non-deductible Expenses</td><td>0.00% (209,255)</td><td>0.00% -</td></tr> <tr> <td>Adjustment Relating to Prior Period Deferred Tax</td><td>0.24% 27,903,315</td><td>0.00% -</td></tr> <tr> <td>Income Taxed at Reduced Rate</td><td>-0.29% (33,966,155)</td><td>-0.35% (35,188,223)</td></tr> <tr> <td>Effective Income Tax</td><td>22.45% 2,599,167,826</td><td>21.70% 2,173,597,001</td></tr> <tr> <td>Effect of Deferred Tax</td><td>-1.84% (212,719,116)</td><td>0.61% 60,647,819</td></tr> <tr> <td>Effective Current Tax</td><td>20.61% 2,386,448,710</td><td>22.30% 2,234,244,820</td></tr> </table>		July'25 - Dec'25	July'24 - Dec'24		% Taka	% Taka	Profit before Tax	11,576,312,937	10,018,661,350	Income Tax using Corporate Tax Rate	22.50% 2,604,670,411	22.50% 2,254,198,804	Effects of:			Income Exempted from Tax	0.01% 769,510	-0.45% (45,413,580)	Non-deductible Expenses	0.00% (209,255)	0.00% -	Adjustment Relating to Prior Period Deferred Tax	0.24% 27,903,315	0.00% -	Income Taxed at Reduced Rate	-0.29% (33,966,155)	-0.35% (35,188,223)	Effective Income Tax	22.45% 2,599,167,826	21.70% 2,173,597,001	Effect of Deferred Tax	-1.84% (212,719,116)	0.61% 60,647,819	Effective Current Tax	20.61% 2,386,448,710	22.30% 2,234,244,820	
	July'25 - Dec'25	July'24 - Dec'24																																				
	% Taka	% Taka																																				
Profit before Tax	11,576,312,937	10,018,661,350																																				
Income Tax using Corporate Tax Rate	22.50% 2,604,670,411	22.50% 2,254,198,804																																				
Effects of:																																						
Income Exempted from Tax	0.01% 769,510	-0.45% (45,413,580)																																				
Non-deductible Expenses	0.00% (209,255)	0.00% -																																				
Adjustment Relating to Prior Period Deferred Tax	0.24% 27,903,315	0.00% -																																				
Income Taxed at Reduced Rate	-0.29% (33,966,155)	-0.35% (35,188,223)																																				
Effective Income Tax	22.45% 2,599,167,826	21.70% 2,173,597,001																																				
Effect of Deferred Tax	-1.84% (212,719,116)	0.61% 60,647,819																																				
Effective Current Tax	20.61% 2,386,448,710	22.30% 2,234,244,820																																				
<b>25. Unrealised Gain/(Loss) on Marketable Securities: Tk. 26,008,281</b>																																						
Closing Unrealised Gain/(Loss)	(563,612,203)	(179,487,280)																																				
Opening Unrealised Loss/(Gain)	589,620,484	318,792,286																																				
<b>Tk.</b>	<b>26,008,281</b>	<b>139,305,006</b>																																				
<b>26. Net Asset Value (NAV) per Share: Tk. 122.87</b>																																						
Total Assets	136,857,600,645	122,951,021,339																																				
Total Liabilities	(27,942,514,912)	(12,397,775,635)																																				
Net Asset attributable to the Ordinary Shareholders	108,915,085,733	110,553,245,704																																				
Number of Shares outstanding	886,451,010	886,451,010																																				
<b>Tk.</b>	<b>122.87</b>	<b>124.71</b>																																				
<b>27. Earnings per Share (EPS): Tk. 10.13</b>																																						
Net Profit after Tax attributable to Shareholders	8,977,145,111	7,845,064,349																																				
Number of Shares outstanding	886,451,010	886,451,010																																				
<b>Tk.</b>	<b>10.13</b>	<b>8.85</b>																																				
<b>28. Net Operating Cash Flow (NOCF) per Share: Tk. 12.28</b>																																						
Net Cash Generated from Operating Activities (Note - 28.1)	10,884,409,780	6,657,480,845																																				
Number of Shares outstanding	886,451,010	886,451,010																																				
<b>Tk.</b>	<b>12.28</b>	<b>7.51</b>																																				
Increase in Sales Revenue combined with high efficiency in working capital management led to increased Net Operating Cash Flow per Share for the reporting period.																																						
<b>28.1 Reconciliation of Net Profit with Cash Flows Generated from Operating Activities:</b>																																						
<b>Profit after Tax</b>	<b>8,977,145,111</b>	<b>7,845,064,349</b>																																				
Income from Investments (Note - 23)	(3,606,348,263)	(3,053,735,856)																																				
Income Tax Expense	2,599,167,826	2,173,597,001																																				
Adjustments for:																																						
Non-Cash Income/Expenses:																																						
Depreciation	814,413,836	801,112,993																																				
Effect of Exchange Rate Fluctuations	2,867,410	(184,149,451)																																				
(Gain)/Loss on Disposal of Property, Plant and Equipment (Note - 22)	(3,642,987)	(8,686,642)																																				
	813,638,259	608,276,900																																				
(Increase)/Decrease in Current Assets:																																						
Inventories	(152,905,117)	(1,080,473,976)																																				
Trade Receivables	(14,823,734)	(211,729,478)																																				
Other Receivables	(94,366,721)	(409,987)																																				
Advances, Deposits and Prepayments	47,030,325	43,674,652																																				
Increase/(Decrease) in Current Liabilities:																																						
Trade Payables	111,371,448	(175,509,624)																																				
Other Payables	4,026,742,358	2,300,665,651																																				
Accrued Expenses	44,865,420	(25,338,924)																																				
	3,967,913,979	850,878,314																																				
Tax Paid	12,751,516,912	8,424,080,708																																				
	(1,867,107,132)	(1,766,599,863)																																				
<b>Net Cash Generated from Operating Activities</b>	<b>10,884,409,780</b>	<b>6,657,480,845</b>																																				
<b>29. Contingent Liabilities:</b>																																						
1. Liabilities for at Sight Letter of Credits as of 31 December 2025 was Tk. 8,454,777,731.																																						
2. Corporate Guarantee in favour of Square Pharmaceuticals Kenya EPZ Ltd. for USD 8.00 Million is still in place with due approval of Bangladesh Bank.																																						



		July'25 - Dec'25	July'24 - Dec'24
<b>30. Related Party Transactions:</b>			
<b>30.1 Transaction with Key Management Personnel:</b>			
Amount of compensation paid to Key Management Personnel including Board of Directors during the Period:			
Short-Term Employee Benefits	Tk.	279,624,437	245,508,915
Post-Employment Benefits	Tk.	28,123,230	4,619,095
Other Long-Term Benefits		-	-
Termination Benefits		-	-
Share-Based Payment		-	-
<b>30.2 Transaction with Other Related parties:</b>			
<b><u>A. Associates:</u></b>			
<b>Square Textiles PLC. (46.36% share):</b>			
Opening Balance		-	-
Addition during the Period		4,003,040,600	5,386,200,000
Paid during the Period		(4,003,040,600)	(5,386,200,000)
Closing Balance	Tk.	-	-
<b>Square Fashions Ltd. (48.63% share):</b>			
Opening Balance		-	-
Addition during the Period		2,588,898,788	11,846,581,422
Paid during the Period		(2,588,898,788)	(11,846,581,422)
Closing Balance	Tk.	-	-
<b>Square Hospitals Ltd. (49.94% share):</b>			
Opening Balance		-	-
Addition during the Period		(25,634,295)	22,752,620
Paid during the Period		25,953,795	(22,752,620)
Closing Balance	Tk.	319,500	-
<b><u>B. Subsidiaries:</u></b>			
<b>Square Lifesciences Ltd. (99.95% share):</b>			
Opening Balance		(7,135,337,513)	(1,616,263,960)
Addition during the Period		(9,477,165,393)	8,594,445,852
Paid during the Period		5,076,604,702	(10,712,247,475)
Closing Balance (Payable)	Tk.	(11,535,898,204)	(3,734,065,583)
<b><u>C. Subsidiaries of Associates:</u></b>			
<b>Square Denims Ltd. (Subsidiary of Square Fashions Ltd.):</b>			
Opening Balance		-	-
Addition during the Period		3,185,453,236	778,781,543
Paid during the Period		(3,185,453,236)	(778,781,543)
Closing Balance	Tk.	-	-
<b>Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.):</b>			
Opening Balance		-	-
Addition during the Period		1,414,918,505	279,637,035
Paid during the Period		(1,414,918,505)	(279,637,035)
Closing Balance	Tk.	-	-
<b><u>D. Others:</u></b>			
<b>Square InformatiX Ltd. (Service Provider):</b>			
Opening Balance		(7,012,446)	-
Addition during the Period		(41,859,241)	95,681,244
Paid during the Period		47,275,465	(95,681,244)
Closing Balance (Payable)	Tk.	(1,596,221)	-
<b>Square Toiletries Ltd. (Supplier):</b>			
Opening Balance		(11,895,085)	-
Addition during the Period		(104,998,524)	87,214,911
Paid during the Period		116,872,376.82	(87,214,911)
Closing Balance (Payable)	Tk.	(21,232)	-
<b>Square Food &amp; Beverages Ltd. (Supplier):</b>			
Opening Balance		(11,983,072)	-
Addition during the Period		(101,828,804)	81,591,004
Paid during the Period		113,811,876	(81,591,004)
Closing Balance (Payable)	Tk.	-	-
<b>Square Securities Management Ltd. (Portfolio Manager):</b>			
Opening Balance		100,608,498	10,037,386
Addition during the Period		343,617,829	460,198,609
Paid during the Period		(441,985,942)	(423,421,019)
Closing Balance	Tk.	2,240,385	46,814,976
<b>Pharma Packages (Pvt.) Ltd. (Supplier):</b>			
Opening Balance		(9,095,192)	71,489,278
Addition during the Period		(30,653,445)	161,730,651
Paid during the Period		47,482,050	(223,485,460)
Closing Balance	Tk.	7,733,414	9,734,469
<b>AEGIS Services Ltd. (Service Provider):</b>			
Opening Balance		-	-
Addition during the Period		(226,838,013)	231,276,924
Paid during the Period		215,470,002	(231,276,924)
Closing Balance (Payable)	Tk.	(11,368,011)	-